Sequential Design = Inflation likely… [RSABE / ABEL]

posted by Helmut Homepage – Vienna, Austria, 2014-09-30 17:03 (3878 d 21:10 ago) – Posting: # 13621
Views: 12,117

Hi ElMaestro

❝ It is an interesting quote but I do not understand much of its implications, to be honest. That might be just because I am rather inexperienced with rsABE etc.


See Fig.3 from Davit et al.*

[image]


Is this a sequential design or not? Forget the protocol review, just look at the left branch. Will the type I error be inflated? In some cases, yes. Remember that in con­ven­tio­nal (unscaled) ABE the empiric α for some combinations of sample size and CV is substantially lower than the nominal α of 0.05. Similar here. If we don’t adjust α, the lower empiric than nominal level of TOST will protect us – maybe. But: We can expect to face inflation, especially close to CVWR 30%.

❝ […] FDA have gone full tilt ahead with population BE for budesonide and other inhalation drugs at the in vitro level. I wonder how the pieces actually fit together.


Not my field of expertise. Go and have my next puff now.



Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,672 registered users;
68 visitors (0 registered, 68 guests [including 6 identified bots]).
Forum time: 14:14 CEST (Europe/Vienna)

Only dead fish go with the current.    Scuba divers' proverb

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5